Print Page  Close Window

SEC/Sec. 16 Filings

8-K
ORASURE TECHNOLOGIES INC filed this Form 8-K on 08/08/2018
Entire Document
 << Previous Page | Next Page >>

More than four months ago I became CEO and have gotten to know the Company on a deeper level.  I can say without hesitation, I’m even more impressed by the strength of our management team, the quality of our products and the outlook for OraSure.  I will continue to advance innovation here at the Company because I believe that it is crucial to our continued growth.  I intend to do this by prioritizing efforts to foster a culture that empowers our management team to innovate and then rewards them for their success. I am confident that we have the right strategy in place and the other necessary pieces to take the Company to the next level.

With that, we will now take your questions. Operator, please proceed.

* * * *

[Q&A session]

 

Final Conclusion – Steve Tang

Thank you for participating on today’s call and for your continued interest in OraSure. Have a good afternoon and evening.

Important Information

This document contains certain forward-looking statements, including with respect to expected revenues and earnings/loss per share. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: ability to market and sell products, whether through our internal, direct sales force or third parties; ability to manufacture products in accordance with applicable specifications, performance standards and quality requirements; ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications or applications for existing products; ability to comply with applicable regulatory requirements; ability to effectively resolve warning letters, audit observations and other findings or comments from the U.S. Food and Drug Administration (“FDA”) or other regulators; changes in relationships, including disputes or disagreements, with strategic partners or other parties and reliance on strategic partners for the performance of critical activities under collaborative arrangements; ability to meet increased

13

 


 << Previous Page | Next Page >>